⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1592649 | 1.00 | — | — | |
| SCHEMBL924305 | 0.82 | — | — | |
| SCHEMBL15514539 | 0.73 | — | — | |
| SCHEMBL6322553 | 0.67 | — | — | |
| SCHEMBL156244 | 0.66 | — | — | |
| SCHEMBL25245675 | 0.58 | — | — | |
| SCHEMBL25356175 | 0.57 | — | — | |
| SCHEMBL25355176 | 0.57 | — | — | |
| SCHEMBL25246055 | 0.56 | CA1 (0.39) | — | |
| SCHEMBL3327061 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196283-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-12 | — | — | WO | claimed |
| US-8530504-B2 | Pyrazolothiazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-09-10 | — | — | US | claimed |
| WO-2013038308-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2013-03-21 | — | — | WO | claimed |
| EP-2487178-A1 | PYRAZOLOTHIAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2012-08-15 | — | — | EP | claimed |
| US-20110086882-A1 | PYRAZOLOTHIAZOLE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-04-14 | — | — | US | claimed |
| US-20090275651-A1 | Alcanoic Acid Amides Substituted by Saturated O-Heterocycles | SPEEDEL EXPERIMENTA AG | 2009-11-05 | — | — | US | claimed |
| US-20080176947-A1 | Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors | NOVARTIS AG (CH) | 2008-07-24 | — | — | US | claimed |
| EP-1937248-A2 | ALCANOIC ACID AMIDES SUBSTITUTED BY SATURATED O-HETEROCYCLES | Speedel Experimenta AG (CH) | 2008-07-02 | — | — | EP | claimed |
| WO-2007031557-A2 | ALCANOIC ACID AMIDES SUBSTITUTED BY SATURATED O-HETEROCYCLES | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-22 | — | — | WO | claimed |
| US-20240166669-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| WO-2024091409-A1 | TRICYCLIC DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2024-05-02 | — | — | WO | disclosed |
| WO-2024054625-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KRAS G12D VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024023330-A1 | SUBSTITUTED BICYCLIC HETEROARYL SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | NODUS ONCOLOGY LIMITED (GB) | 2024-02-01 | — | — | WO | disclosed |
| EP-4311829-A1 | SUBSTITUTED BICYCLIC HETEROARYL SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | Nodus Oncology Limited (GB) | 2024-01-31 | — | — | EP | disclosed |
| WO-2007031558-A1 | 5-AMINO-4-HYDROXY-7- (IMIDAZO [1,2-A] PYRIDIN-6- YLMETHYL)-8-METHYL-NONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007031557-A2 | ALCANOIC ACID AMIDES SUBSTITUTED BY SATURATED O-HETEROCYCLES | SPEEDEL EXPERIMENTA AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| WO-2006103275-A1 | 3,4,5-SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006095020-A1 | HETEROCYCLIC-SUBSTITUTED ALKANAMIDES USEFUL AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006082401-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006082400-A1 | INDAN-AMIDE DERIVATIVES WITH GLYCOGEN PHOSPHORYLASE INHIBITORY ACTIVITY | ASTRAZENECA AB (SE) | 2006-08-10 | — | — | WO | disclosed |